LEO Pharma A/S agreed to acquire the global rights for skin disease drug Spevigo from Boehringer Ingelheim GmbH, as the ...

Boehringer Ingelheim and LEO Pharma have signed an exclusive global license and transfer agreement to commercialize and ...

For the second time this year, Leo Pharma has struck a partnership with a major drugmaker, this time paying Boehringer ...

The IL-36 inhibitor is being explored for additional inflammatory skin conditions, aiming to expand treatment options for underserved patient groups.

Guselkumab and risankizumab for psoriasis have the highest rates of drug survival among biologics measured and a comparable safety profile.

The trial aims to assess the safety and efficacy of tralokinumab 300mg administered biweekly as a single agent.

Apogee is pitching APG777 as a 'best-in-class' IL-13 inhibitor that could offer robust efficacy and less-frequent dosing than ...

Germany has become the debut market for LEO Pharma's Anzupgo, the first topical treatment specifically approved for chronic hand eczema (CHE). The launch of pan-JAK inhibitor Anzupgo (delgocitinib ...

Pope Leo interrupted a two-week vacation on Wednesday to celebrate a special Mass exhorting Catholics to exercise care for ...

COMMENTARY: Despite what desires remain in Rome for full communion, it is a complete impossibility when the two most ...

LIMA, Peru (AP) — Pope Leo XIV has said there should be no tolerance in the Catholic Church for any type of abuse – sexual, spiritual or abuse of authority — and called for “transparent processes” to ...

India's Torrent Pharmaceuticals said on Sunday it will acquire a 46.39% controlling stake in smaller peer JB Chemicals and Pharmaceuticals from New York-based investment firm KKR , and plans to ...